Roscovitine is an inhibitor of CDKs (1, 2, 5, 7, 9, 12) and L-type Ca2+ channels; it exhibits anti-inflammatory and anticancer activities. Roscovitine resolves neutrophil-driven inflammation. In B-cell lymphoma cells, roscovitine induces cell cycle arrest and apoptosis and inhibits proliferation.
| Cas No. | 186692-46-6 |
|---|---|
| Purity | ≥98% |
| Formula | C19H26N6O |
| Formula Wt. | 354.45 |
| Chemical Name | 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino- 9-isopropylpurine |
| IUPAC Name | DISCONTINUED |
| Synonym | Seliciclib, CYC202 |
| Melting Point | 106-109°C |
| Solubility | Soluble in DMSO or chloroform. |
| Appearance | White crystalline solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | R5774 MSDS PDF |
|---|---|
| Info Sheet | R5774 Info Sheet PDF |
Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol. 2009 Oct;158(4):1004-16. PMID: 19775281.
Yarotskyy V, Elmslie KS. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br J Pharmacol. 2007 Oct;152(3):386-95. PMID: 17700718.
Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007 Jan;48(1):158-67. PMID: 17325859.
